- Home
- CRNX vs INM Comparison
CRNX vs INM Comparison
Compare CRNX & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- INM
- Stock Information
- Founded
- CRNX 2008
- INM 1981
- Country
- CRNX United States
- INM Canada
- Employees
- CRNX N/A
- INM N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- CRNX Health Care
- INM Health Care
- Exchange
- CRNX Nasdaq
- INM Nasdaq
- Market Cap
- CRNX 2.8B
- INM 5.0M
- IPO Year
- CRNX 2018
- INM N/A
- Fundamental
- Price
- CRNX $43.50
- INM $1.88
- Analyst Decision
- CRNX Buy
- INM
- Analyst Count
- CRNX 12
- INM 0
- Target Price
- CRNX $74.45
- INM N/A
- AVG Volume (30 Days)
- CRNX 1.4M
- INM 104.1K
- Earning Date
- CRNX 11-06-2025
- INM 11-13-2025
- Dividend Yield
- CRNX N/A
- INM N/A
- EPS Growth
- CRNX N/A
- INM N/A
- EPS
- CRNX N/A
- INM N/A
- Revenue
- CRNX $1,392,000.00
- INM $4,942,633.00
- Revenue This Year
- CRNX $420.79
- INM N/A
- Revenue Next Year
- CRNX $993.85
- INM N/A
- P/E Ratio
- CRNX N/A
- INM N/A
- Revenue Growth
- CRNX 0.51
- INM 7.50
- 52 Week Low
- CRNX $24.10
- INM $1.72
- 52 Week High
- CRNX $62.53
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- CRNX 57.17
- INM 34.36
- Support Level
- CRNX $41.12
- INM $1.80
- Resistance Level
- CRNX $44.70
- INM $2.14
- Average True Range (ATR)
- CRNX 2.05
- INM 0.10
- MACD
- CRNX -0.26
- INM -0.03
- Stochastic Oscillator
- CRNX 59.64
- INM 17.39
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.